B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar MehtaAuayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. VoseA, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Original languageEnglish (US)
Pages (from-to)650-661
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Guidelines
Phosphatidylinositol 3-Kinase
Cell- and Tissue-Based Therapy
Non-Hodgkin's Lymphoma
Therapeutics
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology

Cite this

Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., ... Sundar, H. (2019). B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(6), 650-661. https://doi.org/10.6004/jnccn.2019.0029

B-cell lymphomas, version 3.2019 : Featured updates to the NCCN Guidelines. / Zelenetz, Andrew D.; Gordon, Leo I.; Abramson, Jeremy S.; Advani, Ranjana H.; Bartlett, Nancy L.; Caimi, Paolo F.; Chang, Julie E.; Chavez, Julio C.; Christian, Beth; Fayad, Luis E.; Glenn, Martha J.; Habermann, Thomas M.; Harris, Nancy Lee; Hernandez-Ilizaliturri, Francisco; Kaminski, Mark S.; Kelsey, Christopher R.; Khan, Nadia; Krivacic, Susan; LaCasce, Ann S.; Mehta, Amitkumar; Nademanee, Auayporn; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Roberts, Kenneth B.; Smith, Stephen D.; Snyder, Erin D.; Swinnen, Lode J.; VoseA, Julie M.; Dwyer, Mary A.; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, No. 6, 01.01.2019, p. 650-661.

Research output: Contribution to journalArticle

Zelenetz, AD, Gordon, LI, Abramson, JS, Advani, RH, Bartlett, NL, Caimi, PF, Chang, JE, Chavez, JC, Christian, B, Fayad, LE, Glenn, MJ, Habermann, TM, Harris, NL, Hernandez-Ilizaliturri, F, Kaminski, MS, Kelsey, CR, Khan, N, Krivacic, S, LaCasce, AS, Mehta, A, Nademanee, A, Rabinovitch, R, Reddy, N, Reid, E, Roberts, KB, Smith, SD, Snyder, ED, Swinnen, LJ, VoseA, JM, Dwyer, MA & Sundar, H 2019, 'B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 6, pp. 650-661. https://doi.org/10.6004/jnccn.2019.0029
Zelenetz, Andrew D. ; Gordon, Leo I. ; Abramson, Jeremy S. ; Advani, Ranjana H. ; Bartlett, Nancy L. ; Caimi, Paolo F. ; Chang, Julie E. ; Chavez, Julio C. ; Christian, Beth ; Fayad, Luis E. ; Glenn, Martha J. ; Habermann, Thomas M. ; Harris, Nancy Lee ; Hernandez-Ilizaliturri, Francisco ; Kaminski, Mark S. ; Kelsey, Christopher R. ; Khan, Nadia ; Krivacic, Susan ; LaCasce, Ann S. ; Mehta, Amitkumar ; Nademanee, Auayporn ; Rabinovitch, Rachel ; Reddy, Nishitha ; Reid, Erin ; Roberts, Kenneth B. ; Smith, Stephen D. ; Snyder, Erin D. ; Swinnen, Lode J. ; VoseA, Julie M. ; Dwyer, Mary A. ; Sundar, Hema. / B-cell lymphomas, version 3.2019 : Featured updates to the NCCN Guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2019 ; Vol. 17, No. 6. pp. 650-661.
@article{c3deada177ac40c0998f7eec90a75b1b,
title = "B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines",
abstract = "Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15{\%} of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.",
author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Bartlett, {Nancy L.} and Caimi, {Paolo F.} and Chang, {Julie E.} and Chavez, {Julio C.} and Beth Christian and Fayad, {Luis E.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Harris, {Nancy Lee} and Francisco Hernandez-Ilizaliturri and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Nadia Khan and Susan Krivacic and LaCasce, {Ann S.} and Amitkumar Mehta and Auayporn Nademanee and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Roberts, {Kenneth B.} and Smith, {Stephen D.} and Snyder, {Erin D.} and Swinnen, {Lode J.} and VoseA, {Julie M.} and Dwyer, {Mary A.} and Hema Sundar",
year = "2019",
month = "1",
day = "1",
doi = "10.6004/jnccn.2019.0029",
language = "English (US)",
volume = "17",
pages = "650--661",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - B-cell lymphomas, version 3.2019

T2 - Featured updates to the NCCN Guidelines

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Bartlett, Nancy L.

AU - Caimi, Paolo F.

AU - Chang, Julie E.

AU - Chavez, Julio C.

AU - Christian, Beth

AU - Fayad, Luis E.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hernandez-Ilizaliturri, Francisco

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Khan, Nadia

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Mehta, Amitkumar

AU - Nademanee, Auayporn

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Roberts, Kenneth B.

AU - Smith, Stephen D.

AU - Snyder, Erin D.

AU - Swinnen, Lode J.

AU - VoseA, Julie M.

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

AB - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85068138478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068138478&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0029

DO - 10.6004/jnccn.2019.0029

M3 - Article

C2 - 31200358

AN - SCOPUS:85068138478

VL - 17

SP - 650

EP - 661

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 6

ER -